抗血小板聚集药物在心血管疾病的预防与治疗中占有十分重要的地位,但其对血小板的非特异性选择作用一直困扰着人们。如今,一种新型的针对血小板G蛋白偶联受体的药物为我们解决了这个难题。 Anti-platelet aggregation drugs in the prevention and treatment of cardiovascular disease plays a very important position, but its non-specific platelet selection has been plagued people. Nowadays, a new type of drug targeting platelet G protein-coupled receptors has solved this problem for us.